Long-term Efficacy and Persistence of Subcutaneous Infliximab after Switching from Intravenous Infliximab in patients with Crohn's disease: A Real-World Multicenter Prospective Cohort Study in Korea

被引：0

作者：

Kim, K. ^{[1
]}

Hong, S. N. ^{[2
]}

Kang, S. B. ^{[3
]}

Lee, K. M. ^{[4
]}

Koo, J. S. ^{[5
]}

Jung, Y. ^{[6
]}

Yoon, H. ^{[7
]}

Lee, B. J. ^{[8
]}

Lee, H. S. ^{[9
]}

Lee, Y. J. ^{[10
]}

Lim, Y. J. ^{[11
]}

Lee, J. ^{[12
]}

Lee, C. K. ^{[13
]}

Shin, S. Y. ^{[14
]}

Moon, J. M. ^{[14
]}

Seo, J. ^{[1
]}

Lim, H. ^{[1
]}

Choi, C. H. ^{[1
]}

机构：

[1] Chung Ang Univ Hosp, Dept Internal Med, Seoul, South Korea

[2] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Internal Med, Seoul, South Korea

[3] Catholic Univ Korea, Daejeon St Marys Hosp, Dept Internal Med, Daejeon, South Korea

[4] Catholic Univ Korea, St Vincents Hosp, Coll Med, Dept Internal Med, Suwon, South Korea

[5] Korea Univ, Coll Med, Dept Internal Med, Ansan, South Korea

[6] Soonchunhyang Univ, Coll Med, Dept Internal Med, Cheonan, South Korea

[7] Seoul Natl Univ, Bundang Hosp, Dept Internal Med, Seongnam, South Korea

[8] Korea Univ, Coll Med, Dept Internal Med, Seoul, South Korea

[9] Kyungpook Natl Univ, Sch Med, Dept Internal Med, Daegu, South Korea

[10] Keimyung Univ, Sch Med, Dept Internal Med, Daegu, South Korea

[11] Dongguk Univ, Ilsan Hosp, Dept Internal Med, Goyang, South Korea

[12] Chosun Univ, Coll Med, Dept Internal Med, Gwangju, South Korea

[13] Kyung Hee Univ, Sch Med, Dept Internal Med, Seoul, South Korea

[14] Chung Ang Univ, Gwangmyeong Hosp, Dept Internal Med, Gwangmyeong, South Korea

来源：

JOURNAL OF CROHNS & COLITIS | 2025年 / 19卷

关键词：

D O I：

10.1093/ecco-jcc/jjae190.0934

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

P0760

引用

页码：I1466 / I1467

页数：2

共 50 条

[31] Long-term outcome following infliximab therapy in pediatric patients with Crohn disease: Results from a Multicenter study
Hyams, Jeffrey S.
Lerer, Trudy
Pfefferkorn, Marian D.
Kugathasan, Subra
Evans, Jonathan
Otley, Anthony R.
Griffiths, Anne M.
Carvalho, Ryan S.
Mack, David R.
Bousvaros, Athos
Rosh, Joel R.
Mamula, Petar
Moyer, M. Susan
Kay, Marsha H.
Crandall, Wallace
Oliva-Hernker, Maria
Keljo, David
LeLeiko, Neal S.
Markowitz, James
GASTROENTEROLOGY, 2008, 134 (04) : A134 - A135
[32] Clinical efficacy and durability of subcutaneous infliximab in patients with moderate-to-severe inflammatory bowel disease : a real-world data from a Korean multicentre prospective cohort study
Kim, K.
Hong, S. N. H.
Kang, S. B. K.
Lee, K. M.
Koo, J. S. K.
Jung, Y.
Lee, B. J. L.
Yoon, H. Y.
Kim, H. W.
Lim, Y. J.
Lee, H. S.
Lee, Y. J.
Lee, J.
Lee, C. K.
Moon, J. M.
Shin, S. Y.
Seo, J.
Choi, C. H.
JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1410 - I1412
[33] Safety and efficacy of transitioning inflammatory bowel disease patients from intravenous to subcutaneous infliximab: a single-center real-world experience
Jeffrey, Angus W.
Abu-Rgeef, Reeham
Picardo, Sherman
Menon, Shankar
So, Kenji
Venugopal, Kannan
ANNALS OF GASTROENTEROLOGY, 2023, : 549 - 554
[34] EFFICACY AND SAFETY OF ELECTIVE SWITCHING OF INFLAMAMTORY BOWEL DISEASE PATIENTS FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB: A MULTI-CENTRE COHORT STUDY
Smith, Philip J.
Critchley, Lisa
Storey, Daniel
Gregg, Belle
Stenson, June E.
Kneebone, Andrew
Rimmer, Tracy
Burke, Stevena E.
Hussain, Shamas
Teoh, Wan Yi
Vazeille, Stephan
Serna, Solange
Steel, Alan
Derbyshire, Edmund
Collins, Paul
Dibb, Martyn
Flanagan, Paul K.
Probert, Christopher
Verma, Ajay M.
Subramanian, Sreedhar
GASTROENTEROLOGY, 2022, 162 (07) : S89 - S90
[35] EFFICACY AND SAFETY OF ELECTIVE SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB: A MULTI-CENTRE COHORT STUDY
Smith, Philip J.
Storey, Daniel
Gregg, Belle
Critchley, Lisa
Stenson, June
Kneebone, Andrew
Rimmer, Tracy
Burke, Stevena
Teoh, Wan Yi
Vazeille, Stephan
Serna, Solange
Bond, Ashley
Steel, Alan
Dibb, Martyn
Collins, Paul
Derbyshire, Edmund
Bodger, Keith
Probert, Christopher
Verma, Ajay
Subramanian, Sreedhar
GUT, 2021, 70 : A84 - A84
[36] Long-term response rates to infliximab therapy for Crohn's disease in an outpatient cohort
Teshima, Christopher W.
Thompson, Adrienne
Dhanoa, LeRose
Dieleman, Levinus A.
Fedorak, Richard N.
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2009, 23 (05): : 348 - 352
[37] Efficacy, safety, and pharmacokinetics after switching from infliximab originator to biosimilar SB2 in inflammatory bowel disease patients: A long-term observational, prospective cohort study
Fischer, S.
Mesfin, S.
Klenske, E.
Schmitt, H.
Vitali, F.
Hirschmann, S.
Ramming, A.
Zundler, S.
Rath, T.
Krebs, S.
Doerje, F.
Uter, W.
Nagore, D.
Meyer, S.
Neurath, M. F.
Atreya, R.
JOURNAL OF CROHNS & COLITIS, 2020, 14 : S466 - S467
[38] Long-term safety and efficacy of subcutaneous pasireotide in patients with Cushing's disease: interim results from a long-term real-world evidence study
Manetti, Luca
Deutschbein, Timo
Schopohl, Jochen
Yuen, Kevin C. J.
Roughton, Michael
Kriemler-Krahn, Ulrike
Tauchmanova, Libuse
Maamari, Ricardo
Giordano, Carla
PITUITARY, 2019, 22 (05) : 542 - 551
[39] Long-term safety and efficacy of subcutaneous pasireotide in patients with Cushing’s disease: interim results from a long-term real-world evidence study
Luca Manetti
Timo Deutschbein
Jochen Schopohl
Kevin C. J. Yuen
Michael Roughton
Ulrike Kriemler-Krahn
Libuse Tauchmanova
Ricardo Maamari
Carla Giordano
Pituitary, 2019, 22 : 542 - 551
[40] Long-term real life efficacy of infliximab in Crohn's disease: Brazilian initial experience since 1999
Arceu, Scanavini Neto
Natalia, Queiroz
Marcelo, Borba
Carlos, Sobrado
Magaly, Teixeira
Edesio, Silva-Fillho
Sergio, Nahas
Ivan, Cecconello
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S4 - S4

← 1 2 3 4 5 →